奥氮平联合阿戈美拉汀对精神分裂症伴抑郁症状患者PANSS评分及抑郁水平的影响

Effect of Olanzapine Combined with Agomelatine on PANSS Score and Depression Level in Patients with Schizophrenia and Depressive Symptoms

目的:探讨奥氮平联合阿戈美拉汀对精神分裂症伴抑郁症状患者阳性和阴性症状量表(PANSS)评分及抑郁水平的影响。方法:选取2021年9月—2022年6月赣州市第三人民医院收治的精神分裂症伴抑郁症状患者82例,以抽签法分为对照组(41例)、研究组(41例);对照组予奥氮平联合度洛西汀治疗,研究组予奥氮平联合阿戈美拉汀治疗;对比两组PANSS评分、抑郁水平、睡眠状况、认知状况及不良反应。结果:治疗3个月,研究组PANSS、汉密尔顿抑郁量表(HAMD)、匹兹堡睡眠质量指数量表(PSQI)评分均较对照组低,蒙特利尔认知评估量表(MoCA)评分较对照组高,差异均有统计学意义(P<0.05);两组间不良反应发生率对比,差异无统计学意义(P>0.05)。结论:奥氮平联合阿戈美拉汀治疗精神分裂症伴抑郁症状患者可降低PANSS评分,减轻抑郁水平,改善睡眠与认知状况,且不良反应少,安全性佳。

Objective:To investigate the effect of Olanzapine combined with Agomelatine on the positive and negative symptom scale(PANSS)score and depression levels in patients with schizophrenia and depressive symptoms.Method:A total of 82 schizophrenic patients with depressive symptoms admitted to the Third People's Hospital of Ganzhou from September 2021 to June 2022 were selected and divided into the control group(41 cases)and the study group(41 cases)by drawing lots.The control group was treated with Olanzapine combined with Duloxetine,while the study group was treated with Olanzapine combined with Agomelatine.The PANSS score,depression level,sleep quality,cognitive function and adverse reactions were compared between the two groups.Result:After 3 months of treatment,the PANSS,Hamilton depression scale(HAMD)and Pittsburgh sleep quality index(PSQI)scores in the study group were lower than those in the control group,while the Montreal cognitive scale(MoCA)score was higher than that in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Olanzapine combined with Argomepratine in the treatment of patients with schizophrenia and depressive symptoms can lower the PANSS score,lower the level of depression,improve sleep quality and cognitive function,with fewer adverse reactions and good safety.